MedTrace Logo

Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

NCT04811326 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-08-09

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

RADIATION

NB-UVB

radiation

DRUG

Latanoprost

eye drops

Sponsors & Collaborators

  • Shaimaa Fawzy Abdel-rady Abdel-latif

    lead OTHER

Principal Investigators

  • Moustafa A El Taieb, prof. · Prof. and Head of Dermatology, Venereology and Andrology department, Aswan University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2024-02-13
Completion
2024-03-13

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811326 on ClinicalTrials.gov